Full Text
Full text is available in PDF
Background:
The study was conducted to evaluate the effect of chemoembolization on pancreatic cancer liver metastases.
An Innovative Journal in the Field of Radiology
e-ISSN 2008-2711
p-ISSN 1735-1065
Liver Metastases of Pancreatic Cancer: Role of Repetitive Transarterial Chemoembolization (TACE) on Tumor Response and Survival
Authors
1Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
*Corresponding Author: Johann Wolfgang Goethe University Hospital, Frankfurt, Germany. , azizishiraz@yahoo.com. Email: azizishiraz@yahoo.com
Published online:Feb 28, 2014
Article type:Research Article
How to Cite:Azizi A, Naghyb N, Farshid P, M.Balisike E, J.Vogl T. Liver Metastases of Pancreatic Cancer: Role of Repetitive Transarterial Chemoembolization (TACE) on Tumor Response and Survival. I J Radiol. 2014;11(30th Iranian Congress of Radiology):e21438. doi: https://doi.org/10.5812/iranjradiol.21438
Abstract
Patients and Methods:
Thirty-two patients with pancreatic cancer liver metastases who had underwent chemoembolization (48 weeks intervals) were retrospectively enrolled into this study. Size based evaluation (RECIST) and survival indexes were assessed in general and for gender and number of lesions.
Results:
71.87% of patients showed stable disease (SD), 9.37% partial response (PR) and 18.75% progressive disease (PD). Survival rate for 1-, 3-, and 5-years from first TACE was 60%, 25%, and 11% respectively. Median survival time was 16 months and for SD group was 20 months. Progression-free survival for 6 month, 1-, 3- and 5-years was 84%, 57.3%, 20%, and 10%, respectively. There was statistically significant difference between male and female patients in their response. Survival rate for 1- and 5-years for males was 80% and 14% and for females was 47% and 0%. There was no significant difference between oligonodular liver lesion (less than 5) and multinodular (more than 5) groups. Survival rate for 1-and 5-years for oligonodular was 84% and 14% and for multinodular was 50% and 0% respectively.
Conclusions:
Repetitive TACE resulted in a relevant response for the control of liver metastases of pancreatic cancer with considerable median survival time. Interestingly, this study was limited by the low number of subjects to produce significant results.
Highlights
Copyright
© 2014, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
28
Dec
2014
Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma
Kavous Firouznia,
Hossein Ghanaati,
Seyed Moayed Alavian,
Payam Azadeh,
Mohsen Nasiri Toosi,
Arya Haj Mirzaian
,et al.Firouznia K, Ghanaati H, Alavian SM, Azadeh P, Nasiri Toosi M, et al. Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma. Hepat Mon. 2014;14(12):e25792. doi: https://doi.org/10.5812/hepatmon.25792
12
Aug
2013
Safety and Efficacy of Transcatheter Arterial Chemoemboliazation in the Real-Life Management of Unresectable Hepatocellular Carcinoma
Argyro Mazioti,
Nikolaos K. Gatselis,
Christos Rountas,
Kalliopi Zachou,
Dimitrios K. Filippiadis,
Kostantinos Tepetes
,et al.Mazioti A, K. Gatselis N, Rountas C, Zachou K, K. Filippiadis D, et al. Safety and Efficacy of Transcatheter Arterial Chemoemboliazation in the Real-Life Management of Unresectable Hepatocellular Carcinoma. Hepat Mon. 2013;13(8):7070. doi: https://doi.org/10.5812/hepatmon.7070
16
Jul
2025
Prophylactic Interventional Therapy After Hepatectomy for Primary Liver Cancer: A Clinical Comparative Study of FOLFOX-HAIC and TACE
Shuai He,
Wenjie Lou,
Junwei Zhao,
Yuxing Ni,
Haijun Du,
Xiyuan Yang
He S, Lou W, Zhao J, Ni Y, Du H, et al. Prophylactic Interventional Therapy After Hepatectomy for Primary Liver Cancer: A Clinical Comparative Study of FOLFOX-HAIC and TACE. Hepat Mon. 2025;25(1):e160901. doi: https://doi.org/10.5812/hepatmon-160901
4
Oct
2016
Outcomes of Transarterial Chemoembolization With or Without Additional Radiofrequency Ablation in Hepatocellular Carcinoma of 2 to 5 cm in Diameter
Mi-Young Kim,
Jin Woong Kim,
Dae-Seong Myung,
Chung-Hwan Jun,
Wan-Sik Lee,
Yang Jun Kang
,et al.Kim M, Kim JW, Myung D, Jun C, Lee W, et al. Outcomes of Transarterial Chemoembolization With or Without Additional Radiofrequency Ablation in Hepatocellular Carcinoma of 2 to 5 cm in Diameter. I J Radiol. 2017;14(1):e13484. doi: https://doi.org/10.5812/iranjradiol.39515
23
Feb
2026
Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma Patients
Peijie Xia,
Aibing Xu,
Siyuan Tian,
Honghua Huang,
Miao Ouyang,
Shengnan Huang
,et al.Xia P, Xu A, Tian S, Huang H, Ouyang M, et al. Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma Patients. Hepat Mon. 2026;26(1):e168214. doi: https://doi.org/10.5812/hepatmon-168214
Cited by
- Scopus by DOI: 0
Last Update: 2 weeks ago
- Scopus by Title: 48
Last Update: 2 weeks ago
- Scopus by Title (Ref): 0
Last Update: 2 weeks ago
- CrossRef: 0
Last Update: 6 days ago
- OpenAlex: 5
Last Update: 1 hour ago
- OpenCitations: 0
Last Update: 3 days ago
Comments
Number of Comments:0